ACME Laboratories Ltd 2023 AR2
The report for the fiscal year 2022-2023 highlights ACME Laboratories' achievement of US FDA approval for its Oral Solid Dosage Unit, enabling exports to the US market. The company reported a revenue growth of 12.95%, reaching BDT 26,947.71 million, and launched 28 new products for the first time in Bangladesh. Sustainability efforts are centered on the Triple Bottom Line approach, focusing on People, Planet, and Profit, including the recycling of 500,000 liters of water daily through its Effluent Treatment Plant. Additionally, the company is progressing with its Active Pharmaceutical Ingredients project to enhance self-sufficiency in raw material production.
Company: ACME Laboratories Ltd
Sector: Manufacturing
Country: Bangladesh
Year: 2023
Type: AR2
Pages: 212
Back to company
ACME Laboratories Ltd
Annual Report
The report for the fiscal year 2022-2023 highlights ACME Laboratories' achievement of US FDA approval for its Oral Solid Dosage Unit, enabling exports to the US market. The company reported a revenue growth of 12.95%, reaching BDT 26,947.71 million, and launched 28 new products for the first time in Bangladesh. Sustainability efforts are centered on the Triple Bottom Line approach, focusing on People, Planet, and Profit, including the recycling of 500,000 liters of water daily through its Effluent Treatment Plant. Additionally, the company is progressing with its Active Pharmaceutical Ingredients project to enhance self-sufficiency in raw material production.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees